ACE-083
Phase 2Small molecule
Merck & Co.ACE-083 is one of 13 small molecule programs targeting Charcot-Marie-Tooth disease. It is currently in Phase 2.
2
Indications
4
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Charcot-Marie-Tooth Disease
#DrugCompanyPhaseTrials
1Lioresal
NovartisApproved
Mexitil
Boehringer IngelheimApproved
Coenzyme Q10
MMclean Hospital
Phase 2
Engensis
HHelixmith Co., Ltd.
Phase 2
NMD670
NNMD Pharma A/S
Phase 2
ACE-083
Merck & Co.Phase 2
FLX-787-ODT
FFlex Pharma, Inc.
Phase 2
EN001
EENCell
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ACE-083. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company